Tech

Intellia Stock Rises as FDA Lifts MAGNITUDE Hold (NTLA)

The FDA has lifted the MAGNITUDE Phase 3 clinical hold on Intellia Therapeutics' nexiguran ziclumeran (nex-z) for ATTR-CM. The decision, paired with mitigations like enhanced liver monitoring, could accelerate data readouts for a pivotal trial that paused in October 2025 after a safety signal. Intellia shares moved higher as investors priced in faster progression to potential data readouts.

📅 March 02, 2026
⏱️ 2 min read
Intellia Stock Rises as FDA Lifts MAGNITUDE Hold (NTLA)

Key Takeaways

  • FDA lifts the MAGNITUDE Phase 3 hold on nex-z for ATTR-CM, allowing continued enrollment.
  • NTLA stock rose about 8.9% intraday and sits roughly 20% higher over the last 12 months.
  • MAGNITUDE enrolls about 1,200 patients; MAGNITUDE-2 enrolls about 60 patients.
  • Mitigations include enhanced liver monitoring, short-term steroids after dosing if transaminases rise, and tighter liver abnormal exclusions.
  • Next milestones: complete enrollment and data readouts for MAGNITUDE and MAGNITUDE-2, with potential regulatory submissions if endpoints are met.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Intellia Therapeutics Inc (NTLA) Biotechnology company
  • FDA - U.S. Food and Drug Administration Regulatory agency lifting hold
  • Chardan Capital Investment bank mentioned in coverage and targets
  • HC Wainwright & Co. Investment bank mentioned in coverage and targets

MarketMoodz Analysis

What this means for investors: lifting the hold reduces regulatory risk and could accelerate the pivotal MAGNITUDE timeline, with earlier access to efficacy data and potential regulatory submission if endpoints are met. Still, liver safety remains a key risk factor to watch as data readouts unfold.

Historical context: The FDA has lifted similar holds in the past after enhanced monitoring and protocol tweaks, shaping expectations for other ATTR programs and gene-editing efforts. This move aligns with a pattern of safety-driven pauses that, when mitigated effectively, can re-open pivotal-path timelines for innovative therapies.

What to watch next: completion of MAGNITUDE and MAGNITUDE-2 enrollment, upcoming data readouts, and any updated safety monitoring or regulatory filings that could influence partnering or financing decisions.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial